Vermillion secures $17.6M to expand its push for ovarian cancer Dx

Vermillion ($VRML) pulled in $17.6 million through the sale of warrants, completing a $31 million equity financing first disclosed in May. The Austin, TX, diagnostics outfit said that Oracle Investment Management, Jack Schuler, Matthew Strobeck and other investors exercised their warrants in the transaction, purchasing 12.1 million shares of common stock at $1.46 per share. The funding will help the company boost sales and reimbursement efforts for Ova1, its pre-surgery algorithmic blood test designed to screen for ovarian cancer. Item

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.